Cyclo Therapeutics Inc. (NASDAQ: CYTH) Stock Information | RedChip

Cyclo Therapeutics Inc. (NASDAQ: CYTH)


$0.6155
+0.0135 ( +4.32% ) 63.0K

Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.

Market Data


Open


$0.6155

Previous close


$0.6020

Volume


63.0K

Market cap


$16.53M

Day range


$0.5690 - $0.6300

52 week range


$0.5690 - $2.1150

SEC Filings


Form Type Description Pages Date
10-k/a Quarterly Reports 16 Apr 29, 2024
10-k Annual reports 119 Mar 18, 2024
8-k/a 8K-related 15 Mar 04, 2024
4 Insider transactions 1 Feb 15, 2024
4 Insider transactions 1 Feb 15, 2024
4 Insider transactions 1 Feb 15, 2024
4 Insider transactions 1 Feb 15, 2024
4 Insider transactions 1 Feb 15, 2024
4 Insider transactions 1 Feb 15, 2024
4 Insider transactions 1 Feb 15, 2024

Latest News